Skip to main content
S 1637 119th Congress Senate Health

MVP Act

Introduced: May 7, 2025 See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 7, 2025
Read twice and referred to the Committee on Finance.
May 7, 2025
Introduced in Senate
 Votes taken on this bill 4
DateChamberWhat was voted onResultYes–No
May 11, 2004 Senate · vote #91 On Passage of the Bill S. 1637 Passed 925 See who voted →
May 11, 2004 Senate · vote #87 On the Cloture Motion S. 1637 Agreed To 908 See who voted →
Apr 7, 2004 Senate · vote #67 On the Cloture Motion S. 1637 Rejected 5047 See who voted →
Mar 24, 2004 Senate · vote #60 On the Cloture Motion S. 1637 Rejected 5147 See who voted →
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Medicaid VBPs for Patients Act or the MVP Act

This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)

The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.

Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.

What's happening now May 7, 2025

Read twice and referred to the Committee on Finance.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 24

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

See all 24 filings →
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1637: MVP Act. 119th Congress. Open America. https://openamerica.io/bill/119-S-1637/
MLA
"S. 1637: MVP Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-1637/.
Bluebook (legal)
S. 1637, 119th Cong. (2026), https://openamerica.io/bill/119-S-1637/.
Markdown link
[S. 1637: MVP Act](https://openamerica.io/bill/119-S-1637/)
Report a problem